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BACKGROUND: Clinical performance of the novel high-
sensitivity cardiac troponin I (Siemens-hs-cTnI-Centaur)
assay is unknown. We aimed to clinically validate the
Siemens-hs-cTnI-Centaur assay and develop 0/1-h and
0/2-h algorithms.
METHODS: We enrolled patients presenting to the emer-
gency department with symptoms suggestive of acute
myocardial infarction (AMI). Final diagnoses were cen-
trally adjudicated by 2 independent cardiologists includ-
ing all clinical information twice: first, using serial hs-
cTnT (Roche-Elecsys, primary analysis); second, using
hs-cTnI (Abbott-Architect, secondary analysis) measure-
ments in addition to the clinically applied (hs)-cTn.
Siemens-hs-cTnI-Centaur was measured at presentation,
1 h, and 2 h. The primary objective was a direct compar-
ison of diagnostic accuracy, quantified by the area under
the ROC curve (AUC), of Siemens-hs-cTnI-Centaur vs
the 2 established hs-cTn assays (Roche-hs-cTnT-Elecsys,
Abbott-hs-cTnI-Architect). Secondary objectives included
the development of Siemens-hs-cTnI-Centaur-specific
0/1-h and 0/2-h algorithms.
RESULTS: AMI was the final diagnosis in 318 of 1755
(18%) patients (using Roche-hs-cTnT-Elecsys for adjudi-
cation). The AUC at presentation for Siemens-hs-cTnI-
Centaur was 0.94 (95% CI, 0.92–0.96) and comparable
with 0.95 (95% CI, 0.93–0.97) for Roche-hs-cTnT-
Elecsys and 0.93 (95% CI, 0.90–0.96) for Abbott-hs-
cTnI-Architect. Applying the derived Siemens-hs-cTnI-
Centaur 0/1-h algorithm to the validation cohort, 46%
of patients were ruled out (sensitivity, 99.1%; 95% CI,
95.3–100), and 18% of patients were ruled in (specific-
ity, 94.1%; 95% CI, 91.8–95.9). The Siemens-hs-cTnI-
Centaur 0/2-h algorithm ruled out 55% of patients (sensi-
tivity, 100%; 95% CI, 94.1–100), and ruled in 18% of
patients (specificity, 96.0%; 95% CI, 93.1–97.9). Findings
were confirmed in the secondary analyses using serial mea-
surements of Abbott-hs-cTnI-Architect for adjudication.
CONCLUSIONS: Diagnostic accuracy and clinical utility of
the novel Siemens-hs-cTnI-Centaur assay are high and
comparable with the established hs-cTn assays.
ClinicalTrials.gov Identifier: NCT00470587
© 2018 American Association for Clinical Chemistry
Up to 10% of all emergency department (ED)11 consul-
tations are for patients with symptoms suggestive of acute
myocardial infarction (AMI) (1 ). Rapid identification of
AMI as a life-threatening disorder is important for the
early initiation of appropriate evidence-based therapy
(2 ). Electrocardiography (ECG) and cardiac troponin
(cTn) form the diagnostic cornerstones and complement
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clinical assessment in the early rule-out or rule-in of AMI
(2–4).
The introduction of high-sensitivity cardiac tro-
ponin (hs-cTn) assays enabled reliable measurement of
cTn concentrations in the reference interval (5 ) and in-
creased diagnostic accuracy for AMI at presentation (6 ).
Two hs-cTn assays, Roche-hs-cTnT-Elecsys and Abbott-
hs-cTnI-Architect, have been extensively investigated in
large diagnostic studies, including the successful deriva-
tion and validation of early 0/1-h and 0/2-h triage algo-
rithms (3, 7–20).
More recently, the novel hs-cTnI-Centaur assay was
developed. It constitutes only the third hs-cTn assay to
become available for clinical use. Before its possible imple-
mentation into routine clinical care, its performance in pa-
tients presenting with suspected AMI must be thoroughly
examined. Therefore, we set out to compare its diagnostic
accuracy with that of the 2 established hs-cTn assays, and
derived and validated assay-specific 0/1-h and 0/2-h
algorithms.
Materials and Methods
STUDY DESIGN AND POPULATION
Advantageous Predictors of Acute Coronary Syndrome
Evaluation (APACE) is an ongoing prospective interna-
tional multicenter study with 12 centers in 5 countries aim-
ing to advance the early diagnosis of AMI (ClinicalTrials.
gov registry, number NCT00470587) (6, 7, 9, 11, 12, 14,
15, 21–23) (see the Data Supplement that accompanies the
online version of this article at http://www.clinchem.org/
content/vol64/issue9).
ADJUDICATION OF THE FINAL DIAGNOSIS
Central adjudication of the final diagnosis was performed
by 2 independent cardiologists applying the universal
definition of AMI using 2 sets of data: first, all available
medical records obtained during clinical care including
cardiac imaging; second, study-specific assessments in-
cluding serial hs-cTnT concentrations. To address the
uncommon, but previously described, phenomenon of
discrepant results for hs-cTnT and hs-cTnI, we per-
formed a second adjudication using serial hs-cTnI (rather
than hs-cTnT) blood concentrations from study samples
(see the online Data Supplement).
INVESTIGATIONAL hs-cTn MEASUREMENTS
For determination of Siemens-hs-cTnI-Centaur, we used
blood samples collected into serum containers, and for
determination of Abbott-hs-cTnI-Architect and Roche-
hs-cTnT-Elecsys, we used blood samples collected into
serum containers or lithium heparin plasma containers,
respectively. Study-specific blood draws were performed
immediately after informed consent had been obtained at
ED presentation and additionally at 1, 2, 3, and 6 h. Serial
sampling was discontinued when a patient was released or
transferred to the catheter laboratory for acute treatment.
After centrifugation, samples were frozen at 80 °C until
assayed in a blinded fashion at a dedicated core laboratory.
According to the manufacturer, the hs-cTnI-Centaur
assay (ADVIA Centaur TNIH, Siemens Healthcare) has
a population 99th percentile concentration (both sexes)
of 47 ng/L with a corresponding CV of5%. The 99th
percentiles for men and women are 58 ng/L and 39 ng/L,
respectively. Limit of blank, limit of detection (LoD),
and limit of quantification have been determined to be
0.9 ng/L, 2.2 ng/L, and 2.5 ng/L, respectively. The assay
is a dual-capture sandwich immunoassay using magnetic
latex particles and a proprietary acridinium ester for
chemiluminescence detection. The detection reagent is a
recombinant sheep Fab antibody covalently linked to a
trisulfo propyl acridinium ester–BSA conjugate. Trisulfo
propyl acridinium ester is a new generation of high-yield
acridinium esters developed for enhanced chemilumines-
cent detection. Simultaneous addition of solid-phase re-
agent and detection reagent to the sample forms a classic
sandwich immune complex, which is subsequently
washed. Chemiluminescence is initiated and measured.
Relative light units are directly proportional to the cTnI
concentration. The time to first result is 18 min. The
assay meets the current IFCC recommendations for hs-
cTn assays (24, 25 ).
The hs-cTnT-Elecsys assay (Elecsys 2010, Roche
Diagnostics) has a 99th percentile concentration of 14
ng/L with a corresponding CV of 10% at 13 ng/L (5 ).
Limit of blank and LoD have been determined to be 3
ng/L and 5 ng/L, respectively (5 ). The hs-cTnI-Architect
assay (ARCHITECT STAT high-sensitivity troponin I,
Abbott Laboratories) has a 99th percentile concentration
of 26.2 ng/L with a corresponding CV of 5% and an
LoD of 1.9 ng/L (26–28). Estimated glomerular filtra-
tion rate was calculated using the abbreviated Modifica-
tion of Diet in Renal Disease formula (29 ).
DERIVATION OF THE hs-cTnI-CENTAUR 0/1h-ALGORITHM
The hs-cTnI-Centaur 0/1-h algorithm was developed in
a derivation sample of randomly selected (1:1 fashion)
patients with available hs-cTnI-Centaur measurements
at baseline and after 1 h according to the central adjudi-
cation by 2 independent cardiologists using all clinical
information including cardiac imaging and serial hs-cTnT-
Elecsys concentrations (primary adjudication). The 0/1-h
algorithm incorporates hs-cTnI-Centaur concentrations at
presentation and absolute hs-cTnI-Centaur changes
within 1 h (hs-cTnI-Centaur1h  hs-cTnI-Centaur0h),
as well as time since chest pain onset to reflect the concept
of the current hs-cTn 0/1-h algorithms suggested by the
European Society of Cardiology (ESC) (3 ) (see Fig. 4 in
the online Data Supplement). Selection of these param-
eters was based on the high diagnostic accuracy of the
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combination of blood concentrations at presentation
with absolute changes for rule-out and rule-in of AMI
(7, 8, 11, 12, 14, 15, 21, 30, 31 ). Optimal thresholds
for rule-out were selected to allow for a minimal sensitiv-
ity and negative predictive value (NPV) of 99% and were
independent from the assay package insert-specified
thresholds. Optimal thresholds for rule-in were obtained
based on a classification and regression tree (CART) anal-
ysis targeting a minimal positive predictive value (PPV)
of 70% (32, 33 ). Nodes in the CART tree were con-
strained to have a minimal number of 20 cases in parent
and child nodes. If a predefined target performance was
missed in the derivation sample using the CART-derived
thresholds, thresholds were changed stepwise until the
predefined performance was fulfilled.
DERIVATION OF THE hs-cTnI-CENTAUR 0/2h-ALGORITHM
The hs-cTnI-Centaur 0/2-h algorithm was developed in
a derivation sample randomly selected (2:1 fashion to
compensate for the slightly lower number of patients
with available 2-h vs 1-h samples and to ensure a suffi-
cient number of patients in the derivation cohort) of
patients with available hs-cTnI-Centaur measurements
at ED presentation and after 2 h (see the online Data
Supplement) according to the central adjudication by 2
independent cardiologists using all clinical information
including cardiac imaging and serial hs-cTnT-Elecsys
concentrations (primary adjudication).
VALIDATION OF THE hs-cTnI-CENTAUR 0/1-h AND
0/2-h ALGORITHM
The algorithms developed in the derivation samples were
tested for their diagnostic accuracy in internal validation
samples consisting of the remaining subjects. The opti-
mal decision values derived in the derivation sample were
rounded to give whole values in nanograms per liter. The
first validation was done according to the central adjudi-
cation by 2 independent cardiologists using all clinical
information including cardiac imaging and serial hs-
cTnT-Elecsys concentrations. The secondary validation
was done according to the central adjudication by 2
independent cardiologists using all clinical informa-
tion including cardiac imaging and serial hs-cTnI-
Architect concentrations.
FOLLOW-UP AND CLINICAL END POINTS
Clinical follow-up is described in detail in the online
Data Supplement. The coprimary prognostic end points
were overall survival after 30 days and 2 years. The sec-
ondary prognostic end point was major adverse cardiac
events (MACE) defined as the composite of all-cause
mortality, AMI, cardiogenic shock, ventricular tachyar-
rhythmias, or higher degree atrioventricular block at 30
days.
STATISTICAL ANALYSIS
For the primary analysis, serial hs-cTnT-Elecsys concen-
trations were used for final adjudication. For the second-
ary analysis, serial hs-cTnI-Architect concentrations were
used for final adjudication. ROC curves were con-
structed to assess the sensitivity and specificity through-
out the hs-cTn concentrations to compare the ability to
diagnose AMI. Subgroup analyses were performed in pa-
tients presenting to the ED very soon (2 h), soon (3
h), and late (3 h) after chest pain onset/maximum, as
well as in women and men. We further included analysis
using sex-specific cutoffs and investigated the performance
of the ESC 0/3-h algorithm. Biological equivalent concen-
trations were determined by plotting log-transformed hs-
cTnI-Centaur and hs-cTnI-Architect or hs-cTnT-Elecsys
concentrations from the same sample (22). The areas under
the ROC curves (AUC) were compared as recommended
by DeLong et al. (34)or by z-statistic, as appropriate (see the
online Data Supplement).
Safety was assessed as the NPV and the sensitivity of
AMI for rule-out; accuracy for rule-in was assessed as the
PPV and specificity of AMI; and efficacy was quantified
as the percentage of patients triaged toward rule-out or
rule-in for AMI within 1 h or 2 h.
Statistical analyses were performed using IBM SPSS
Statistics for Windows, version 23.0 (SPSS) and Med-
Calc 17.6 (MedCalc Software).
Results
CHARACTERISTICS OF PATIENTS
From April 2006 to February 2013, 1755 patients eligi-
ble for this analysis were enrolled (see Fig. 1 in the online
Data Supplement). Thirty-four percent of patients pre-
sented to the ED within the first 3 h after chest pain onset.
Baseline characteristics of all patients are shown in Table 1,
and those of patients in the derivation and validation co-
horts are shown in Table 2 of the online Data Supplement.
ADJUDICATED FINAL DIAGNOSIS
Of 1755 patients, the adjudicated final diagnosis was AMI
in 318 (18%), unstable angina in 156 (9%), cardiac symp-
toms of origin other than coronary artery disease (e.g.,
tachyarrhythmia, takotsubo cardiomyopathy, heart failure,
and myocarditis) in 238 (14%), noncardiac symptoms in
968 (55%), and unknown in 75 (4%). Final diagnoses ac-
cording to the second final adjudication including hs-cTnI
(Architect) were similar (see the online Data Supplement).
CONCENTRATIONS OF hs-cTnI-CENTAUR AT PRESENTATION
ACCORDING TO FINAL DIAGNOSES
Concentrations of hs-cTnI-Centaur at ED presentation
were significantly higher in patients with AMI as com-
pared with patients with other final diagnoses (P 
0.001). Median concentrations of hs-cTnI-Centaur in
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patients with AMI were 235 ng/L [interquartile range
(IQR), 39 –1018]; with unstable angina, 8.5 ng/L
(IQR, 5.0 –17); with cardiac but not coronary disease,
12 ng/L (IQR, 4.7–36); with noncardiac disease, 4
ng/L (IQR, 2.4 –7.6); and with unknown diagnosis,
4.2 ng/L (IQR, 2.8 –7.0; Fig. 1). Similar findings
emerged according to the second final adjudicated di-
agnosis including hs-cTnI (Architect; see Fig. 2 in the
online Data Supplement).
DIAGNOSTIC ACCURACY FOR ACUTE MYOCARDIAL
INFARCTION
The diagnostic accuracy of measurements obtained at
presentation, as quantified by AUCs, for the hs-cTnI-
Centaur assay was 0.94 (95% CI, 0.92– 0.96) and
comparable with hs-cTnT-Elecsys at 0.95 (95% CI, 0.93–
0.97) and hs-cTnI-Architect at 0.93 (95% CI, 0.90–0.96),
respectively (P  0.370 and P  0.780 for direct com-
parisons; Fig. 2A). For hs-cTnI-Centaur, the AUCs for
Table 1. Baseline characteristics of the patients.a
All patients
(n = 1755)
AMI
(n = 318)
No AMI
(n = 1437) P value
Age, years 62 (49–75) 72 (59–80) 60 (47–73) <0.001
Male sex, n (%) 1216 (69) 231 (73) 985 (69) 0.15
Time from CPOb to ﬁrst blood draw, h 5 (3–10) 5 (3–11) 5 (3–10) 0.41
Early presenters (within 3 h after CPO) 603 (34%) 106 (33%) 497 (35%) 0.67
Risk factors, n (%)
Hypertension 1087 (62) 255 (80) 832 (58) <0.001
Hypercholesterolemia 876 (50) 219 (69) 657 (46) <0.001
Diabetes 317 (18) 84 (27) 233 (16) <0.001
Current smoking 442 (25) 77 (24) 365 (25) 0.69
History of smoking 658 (38) 131 (42) 527 (37) 0.11
History, n (%)
Coronary artery disease 619 (35) 160 (50) 459 (32) <0.001
Previous MI 409 (23) 107 (34) 302 (21) <0.001
Previous revascularization 479 (27) 116 (37) 363 (25) <0.001
Peripheral artery disease 116 (7) 48 (15) 68 (5) <0.001
Previous stroke 89 (5) 24 (8) 65 (5) 0.03
ECG ﬁndings, n (%)
Left bundle branch block 55 (3) 15 (5) 40 (3) 0.07
ST-segment depression 156 (9) 88 (28) 68 (5) <0.001
T-wave inversion 152 (9) 39 (12) 113 (8) 0.01
No signiﬁcant ECG abnormalities 1358 (77) 169 (53) 1189 (83) <0.001
Body mass index, kg/m2 27 (24–30) 26 (24–29) 27 (24–30) 0.47
Laboratory ﬁndings
Creatinine clearance, mL/min/m2 84 (68–100) 72 (54–89) 86 (70–102) <0.001
Chronic medication, n (%)
Aspirin 638 (36) 155 (49) 483 (34) <0.001
Vitamin K antagonists 143 (8) 31 (10) 112 (8) 0.25
-blockers 595 (34) 137 (43) 458 (32) <0.001
Statins 613 (35) 140 (44) 473 (33) <0.001
ACEIs/ARBsc 656 (37) 167 (53) 489 (34) <0.001
Calcium antagonists 236 (13) 59 (19) 177 (12) 0.003
Nitrates 200 (11) 65 (20) 135 (9) <0.001
a Numbers are presented as median (IQR) or numbers (%).
b Chest pain onset.
c Angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers.
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concentrations at 1 h, 2 h, and 3 h were 0.95 (95% CI,
0.93–0.96), 0.95 (95% CI, 0.94–0.97), and 0.97 (95%
CI, 0.95–0.99), respectively (see Table 3A in the online
Data Supplement). Similar findings emerged according
to the second final adjudicated diagnosis including hs-
cTnI (Architect; see Fig. 3A in the online Data Supple-
ment). The diagnostic performances of uniform and sex-
specific cutoffs are summarized in Table 2, and detailed
information is given in the Results section of the online
Data Supplement.
SUBGROUP ANALYSES ACCORDING TO TIME SINCE CHEST
PAIN ONSET AND SEX
Diagnostic accuracy at presentation was also similar in
the predefined subgroups (Fig. 2B; see also Table 3B and
the Results section of the online Data Supplement). Again,
similar findings emerged according to the second final ad-
judicated diagnosis including hs-cTnI (Architect; see Fig.
3B of the online Data Supplement).
hs-cTnI-CENTAUR 0/1-h ALGORITHM
The diagnostic performance of the hs-cTnI-Centaur 0/1-h
algorithm in the derivation cohort is shown in Fig. 3A here
and Fig. 5A of the online Data Supplement.
VALIDATION OF THE hs-cTnI-CENTAUR 0/1-h ALGORITHM
Applying the derived optimal cutoff levels to the internal
validation cohort, 313 of 675 patients (46%) could be
classified as rule-out with a corresponding NPV of
99.7% (95% CI, 97.8–100) and a sensitivity of 99.1%
(95% CI, 95.3–100; see Fig. 3B here and Fig. 5B of the
online Data Supplement). Direct rule-out based on a
single hs-cTnI-Centaur concentration at presentation
was feasible in 111 of 675 patients (16%). One patient
with AMI was missed out of 675 patients with suspected
AMI in the validation sample (see Table 4 in the online
Data Supplement for detailed patient characteristics).
The 0/1-h algorithm classified 120 of 675 patients (18%)
as rule-in with a corresponding PPV of 72.5% (95% CI,
63.6–80.3) and a specificity of 94.1% (95% CI, 91.8–
95.9). Direct rule-in based on a single hs-cTnI-Centaur
concentration at presentation was feasible in 79 of 675
patients (12%). Overall, the hs-cTnI-Centaur 0/1-h al-
gorithm allowed a definite diagnosis after 1 h in 433 of
675 patients (64%; either rule-out or rule-in). The re-
maining 242 of 675 patients (36%) were classified to
observe with an AMI prevalence of 11% (95% CI,
8–15). Similar findings emerged when assessing the di-
agnostic performance of the hs-cTnI-Centaur 0/1-h al-
gorithm in the validation cohort using the second final
Fig. 1. Boxplots showing concentrations of hs-cTnI-Centaur at presentation according to the ﬁnal diagnosis.
Boxes represent medians and IQRs, while whiskers display the smallest and the largest nonoutliers. Rings display outliers further than 1.5
IQRs, and boxes display outliers further than 3 IQRs from the respective end of the box. UA, unstable angina.
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Fig. 2. Diagnostic accuracy of hs-cTn assays at presentation for the diagnosis of AMI.
(A), ROC curves describing the diagnostic performance of the 3 hs-cTn assays at presentation for the diagnosis of AMI. (B), ROC curves
describing the diagnostic performance of the 3 hs-cTn assays at presentation for the diagnosis of AMI in patients presenting to the ED within
3 h after chest pain onset.
1352 Clinical Chemistry 64:9 (2018)
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adjudication including hs-cTnI (Architect; see Fig. 6 in
the online Data Supplement).
DIRECT COMPARISON OF THE hs-cTnI-CENTAUR 0/1-h
ALGORITHM WITH THE ESC 0/1-h ALGORITHMS USING
hs-cTnT-ELECSYS AND hs-cTnI-ARCHITECT
Overall, the diagnostic performance of the hs-cTnI-Centaur
0/1-h algorithm was similar to that of the hs-cTnT-Elecsys
0/1-h algorithm and the hs-cTnI-Architect 0/1-h algorithm
(see Figs. 7 and 8 in the online Data Supplement).
hs-cTnI-CENTAUR 0/2-h ALGORITHM
Optimal thresholds for rule-out and rule-in are shown in
Fig. 3C.
VALIDATION OF THE hs-cTnI-CENTAUR 0/2-h ALGORITHM
Applying the derived optimal thresholds to the internal
validation cohort, 200 of 361 patients (55%) could be
classified as rule-out with a corresponding NPV of 100%
and a sensitivity of 100% (95% CI, 94.1–100; see Fig.
3D here and Fig. 9 in the online Data Supplement).
PROGNOSTIC PERFORMANCE OF THE hs-cTnI-CENTAUR 0/1-h
ALGORITHM
Median follow-up time was 772 days (IQR, 734–915)
with 13 deaths occurring within 30 days and 99 deaths
within 2 years. Cumulative 30-day survival rates were
100%, 98.6%, and 97.5% (log-rank, P  0.002) in the
rule-out, observe, and rule-in groups, respectively. At 2
years, cumulative survival rates were 98.4%, 89.2%, and
85.1%, respectively (log-rank, P  0.001; Fig. 4). Similar
findings emerged regarding MACE-free survival including
the index event (see Fig. 10 in the online Data Supplement).
BIOLOGICAL EQUIVALENT CONCENTRATIONS
Biological equivalent concentrations for hs-cTnI-Centaur
of hs-cTnI-Architect and hs-cTnT-Elecsys are shown in Fig.
11 of the online Data Supplement.
Discussion
This slarge multicenter study was performed to validate
the diagnostic performance and clinical utility of the novel
hs-cTnI-Centaur assay for the early diagnosis of AMI. We
report 9 major findings.
First, the diagnostic accuracy of hs-cTnI-Centaur
was high for concentrations obtained at ED presentation
and at 1-h and 2-h changes and their combinations with
an AUC ranging from 0.94 to 0.97. Second, the diagnos-
tic accuracy of hs-cTnI-Centaur was comparable with the
2 hs-cTn assays already in clinical use: hs-cTnT-Elecsys
and hs-cTnI-Architect. This finding was consistent in the
overall population and in early presenters. Third, as com-
pared with the uniform cutoffs, sex-specific cutoffs pro-
vided slightly higher sensitivity and NPV but lower spec-
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ificity and PPV in women, and slightly lower sensitivity
and NPV but higher specificity and PPV in men.
Whereas the use of the sex-specific 99th percentile in
women seems reasonable for classification of women at
low risk, the use in men seems to be associated with
potential harm. Fourth, the application of the derived
0/1-h algorithm for hs-cTnI-Centaur, defined by con-
centrations at presentation and its absolute change within
1 h, in the internal validation cohort resulted in high
safety in the rule-out zone with an NPV of 99.7% and a
sensitivity of 99.1%, as well as a high PPV in the rule-in
zone for AMI. Only 2 patients were missed, both with
decreasing hs-cTn concentrations possibly because of late
presentation to the ED. Fifth, overall, the performance of
the 0/1-h algorithm for hs-cTnI-Centaur was compara-
ble with that of the established 0/1-h algorithms for hs-
cTnT-Elecsys and hs-cTnI-Architect, and also similar to
their performance in previous studies (3, 7, 21 ). In con-
trast to the established 0/1-h algorithms, the novel hs-
cTnI-Centaur 0/1-h algorithm uses a slightly higher cut-
off (3 ng/L) for direct rule-out instead of its LoD (2
ng/L). This resulted in a greater proportion of patients
ruled out than using the LoD (16% vs 7%; P 0.001).
As with most other early rule-out algorithms, the cutoffs
for rule-out of AMI with the 0/1-h and 0/2-h algorithms
for hs-cTnI-Centaur are low and, therefore, in a range for
Fig. 3. Performance of the hs-cTnI-Centaur 0/1-h and 0/2-h algorithms in the derivation and validation cohort.
Performance of the hs-cTnI-Centaur 0/1-h algorithm in the derivation cohort (A) and validation cohort (B). Delta 1h denotes absolute
(unsigned) change of hs-cTnI within 1 h. Performance of the hs-cTnI-Centaur 0/2-h algorithm in the derivation cohort (C) and validation cohort
(D). Delta 2h denotes absolute (unsigned) change of hs-cTnI within 2 h. NSTEMI, non-ST-elevation myocardial infarction; Sens., sensitivity;
Spec., speciﬁcity. *If chest pain onset >3h before presentation to the ED.
Continued on page 1357
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which the assay has suboptimal precision. This aspect
highlights the need for further independent validation
studies. As it is unknown to what extent the analytical
qualification as an hs-cTnI assay correlates with the diag-
nostic accuracy for AMI as quantified by the AUC and
the clinical utility as quantified by the performance of the
0/1-h and 0/2-h algorithms, it was mandatory to pro-
spectively evaluate them in this large diagnostic study.
Sixth, the application of the derived 0/2-h algorithm for
the hs-cTnI-Centaur, defined by concentrations at pre-
sentation and its absolute change within 2 h, in the in-
ternal validation cohort resulted also in a high NPV and
sensitivity of 100%, as well as a high PPV for AMI. Sev-
enth, the overall efficacy of the novel hs-cTnI-Centaur
0/1-h and 0/2-h algorithms was high by assigning about
70% of patients to either rule-out or rule-in within 1 h or
2 h (rule-out efficacy was even higher for the 0/2-h algo-
rithm), with only about 30% of patients remaining in the
observe zone. Of note, more than one-fourth (28%) of all
patients were either directly ruled out or ruled in for AMI
at presentation based on a single hs-cTnI-Centaur con-
centration without the need for serial hs-cTnI sampling.
Eighth, these findings were internally validated when us-
ing as an additional reference standard for the second
adjudication including serial hs-cTnI concentrations. By
the use of a reference standard including hs-cTnI in ad-
dition to a reference standard including hs-cTnT, this
large diagnostic study of patients presenting with sus-
pected AMI overcame the small but inherent verification
bias of previous studies that used only 1 (hs)-cTn assay
as part of the reference standard (7, 11, 19, 23, 30 ).
Using the second adjudication resulted in final diag-
noses that slightly differed from those using the pri-
mary adjudication. This can be explained by the dif-
ferences among both assays, e.g., by the fact that 99th
percentiles are not biologically equivalent to each
Fig. 3. Continued from page 1356.
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other. This methodological detail further increases the
generalizability of our findings.
Ninth, survival in patients assigned to the rule-out
zone by the 0/1-h algorithm was 100% after 30 days and
98.4% after 2 years, further underscoring the safety of
early discharge from the ED for most patients classified as
rule-out, with further outpatient management as clini-
cally appropriate. Similarly, MACE-free survival within
30 days in patients triaged toward rule-out was high at
99.4%. Of note, the rather high rate of all-cause mortal-
ity during follow-up and MACE within 30 days of the
observe patients can be, at least in part, explained by the
high incidence of chronic diseases, such as chronic heart
failure, that are directly associated with high rates of both
overall mortality and MACE.
The findings of the present study have enormous
clinical implications, as they will allow a substantial num-
ber of additional institutions to clinically introduce hs-
cTn testing into their treatment of patients with sus-
pected AMI and, thereby, to adopt current clinical
practice guideline recommendations without the logistic
challenges and costs of introducing an additional ana-
lyzer exclusively for the measurement of hs-cTn (2–
4, 10 ). These findings also extend and corroborate pre-
vious work with the 2 other hs-cTn assays (3, 7, 19, 30 ).
Accordingly, the same concept and caveats apply to the
most appropriate clinical use of any of the 3 hs-cTn assays
and their respective 0/1-h and 0/2-h algorithms in the
early diagnosis of AMI (3, 7, 11, 15, 19, 30 ). First, these
algorithms should be applied only after ST-segment ele-
vation myocardial infarction (STEMI) has been ruled out
by the ECG performed at presentation. Second, although
the hs-cTnI-Centaur 0/1-h and 0/2-h algorithm had a
high NPV and sensitivity for AMI, they should always be
used in conjunction with all other clinical information,
including a detailed assessment of chest pain characteris-
tics, physical examination, and the ECG. Additional
measurements of hs-cTnI at, e.g., 3 h, are advised when-
ever the patient remains symptomatic or clinical judg-
ment still points to AMI. These will help to detect the
rare but existing phenomenon of delayed release of hs-
cTn into the circulation, particularly in early presenters
(3 ). It will also help detect rare but possible errors in the
handling of the clinical blood samples, e.g., blood sample
of a patient without AMI (and normal hs-cTnI concen-
trations) erroneously attributed to a patient with AMI.
Third, not all patients triaged toward rule-out of AMI are
appropriate candidates for early discharge from the ED.
Fourth, patients triaged toward rule-in generally are can-
didates for early coronary angiography. About 75% of
patients triaged toward rule-in will be found to have
AMI. Most of the remaining patients in the rule-in zone
will still benefit from coronary angiography for diagnos-
tic and possible therapeutic purposes, as they may be
Fig. 4. Short- and long-term survival of patients classiﬁed according to the hs-cTnI-Centaur 0/1-h algorithm.
Kaplan–Meier curves depicting overall survival within 30 days and 720 days according to classiﬁcation of the hs-cTnI-Centaur 0/1-h algorithm.
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found to have takotsubo cardiomyopathy, myocarditis,
or unstable angina (3 ).
Some limitations merit consideration when inter-
preting these findings. First, this study was conducted in
ED patients with symptoms suggestive of AMI. Further
studies are required to quantify the utility of rule-out and
rule-in strategies for patients with either a higher pretest
probability (e.g., in a coronary care unit setting) or for
patients with a lower pretest probability (e.g., in a general
practitioner setting) of AMI, as well as in the inherently
challenging group of critically ill patients. Second, the
data presented were obtained from a prospective diagnostic
study. Studies applying the diagnostic algorithms prospec-
tively for clinical decision-making are warranted. Third, not
all patients with acute chest pain had a second set of labora-
tory measurements at 1 h and later. The most common
reasons for missing blood samples were logistic issues in
the ED that precluded blood draw around the 1-h
window. This limitation is inherent to studies enroll-
ing consecutive patients and is unlikely to have af-
fected the main findings of the present study. Fourth,
although we used the most stringent methodology to
adjudicate the presence or absence of AMI, including
central adjudication by experienced cardiologists, we
still may have misclassified a small number of patients
(4 ). Fifth, our findings are specific to the hs-cTnI-
Centaur assay. The derived 0/1-h and 0/2-h algo-
rithms cannot be generalized to other hs-cTnI assays.
Sixth, we cannot generalize our findings to patients
with terminal kidney failure requiring dialysis because
they were excluded from this study. Finally, we ac-
knowledge that using hs-cTnT, an assay that is differ-
ent from hs-cTnI assays, as the gold standard assay for
the primary validation may not be the ideal way to
validate an hs-cTnI assay. However, we addressed this
potential limitation by use of a secondary adjudication
including serial hs-cTnI concentrations.
In conclusion, the diagnostic accuracy of the novel
hs-cTnI-Centaur assay for AMI is high and comparable
with both well-established hs-cTn assays: hs-cTnT-
Elecsys and hs-cTnI-Architect. Simple algorithms incor-
porating hs-cTnI-Centaur concentrations at presenta-
tion and absolute changes within the first 1 h or 2 h allow
triage toward safe rule-out and accurate rule-in of AMI
within 1 h or 2 h for most patients presenting with chest
pain to the ED.
Additional APACE investigators and contributors
to this article:
Ana Yufera Sanchez,12,13,14 Tobias Breidthardt,12,13,14
Deborah Mueller,12 Lorraine Sazgary,12 Stella Marbot,12
Zaid Sabti,12,14 Dayana Flores,12,14 Riham Mahfouz,12,14
Stefan Osswald,12 Nicolas Schaerli,12,13,14 Michael
Freese,12,14 Claudia Stelzig,12,14 Kathrin Meissner,12,14
Caroline Kulangara,12,14 Samyut Shrestha,12,14 Karin
Grimm,12,13,14 Beate Hartmann,12,14 Ina Ferel,12,14 Beatriz
Lo´pez,14,15 Carolina Fuenzalida,14,15 Esther Rodriguez
Adrada,16 Eva Ganovska´,14,17 Jens Lohrmann,12 Wanda
Kloos,12 Andreas Buser,18 Arnold von Eckardstein,19 Piotr
Muzyk,14,20 Ewa Nowalany-Kozielska,20 Damian
Kawecki,14,20 and Jiri Parenica, MD14,21
Author Contributions: All authors confirmed they have contributed to
the intellectual content of this paper and have met the following 3 require-
ments: (a) significant contributions to the conception and design, acquisi-
tion of data, or analysis and interpretation of data; (b) drafting or revising
the article for intellectual content; and (c) final approval of the published
article.
Authors’ Disclosures or Potential Conflicts of Interest: Upon man-
uscript submission, all authors completed the author disclosure form. Dis-
closures and/or potential conflicts of interest:
Employment or Leadership: None declared.
Consultant or Advisory Role: J. Boeddinghaus, Siemens; R. Tweren-
bold, Roche, Abbott, Brahms, and Siemens; C. Mueller, Abbott, Alere,
Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Car-
diorentis, Novartis, Roche, Siemens, Singulex.
Stock Ownership: None declared.
Honoraria: J. Boeddinghaus, Siemens; R. Twerenbold, Abbott, Sie-
mens, Roche, Singulex, BRAHMS Thermo Scientific; M. Rubini
Gimenez, Abbott; T. Reichlin, Brahms, Roche; C. Mueller, Abbott,
Alere, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS,
Brahms, Cardiorentis, Novartis, Roche, Siemens, Singulex.
Research Funding: Research grants from the Swiss National Science
Foundation, the Swiss Heart Foundation, the KTI, the European
Union, the Stiftung fu¨r kardiovaskuläre Forschung Basel; Abbott,
Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, and Sin-
gulex. J. Boeddinghaus, the University Hospital Basel and Division of
Internal Medicine, the Swiss Academy of Medical Sciences, and the
Gottfried and Julia Bangerter-Rhyner-Foundation; R. Twerenbold, the
Swiss National Science Foundation (P300PB-167803/1); T. Reichlin,
the Goldschmidt-Jacobson-Foundation, the Swiss National Science
Foundation (PASMP3-136995), the Swiss Heart Foundation, the Pro-
fessor Max Cloe¨tta Foundation, the Uniscientia Foundation Vaduz, the
University of Basel and the Department of Internal Medicine, Univer-
sity Hospital Basel; M. Rubini Gimenez, the Swiss Heart Foundation;
C. Mueller, the Swiss National Science Foundation, the Swiss Heart
Foundation, the KTI, the Stiftung fu¨r kardiovaskuläre Forschung Ba-
sel; Abbott, Alere, Astra Zeneca, Beckman Coulter, Biomerieux,
Brahms, Roche, Siemens, Singulex, Sphingotec, and the Department of
12 Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, Univer-
sity Hospital Basel, University of Basel, Basel, Switzerland; 13 Department of Internal
Medicine, University Hospital Basel, University of Basel, Basel, Switzerland; 14 GREAT
network, Rome, Italy; 15 Emergency Department, Hospital Clinic, Barcelona, Catalonia,
Spain; 16 Servicio de Urgencias, Hospital Clı´nico San Carlos, Madrid, Spain; 17 Depart-
ment of Cardiology, University Hospital Brno, Brno, Czech Republic and Medical Fac-
ulty, Masaryk University, Brno, Czech Republic; 18 Blood Transfusion Centre, Swiss Red
Cross, Basel, Switzerland and Department of Hematology, University Hospital Basel,
University of Basel, Basel, Switzerland; 19 Emergency Department of Laboratory Medi-
cine, University Hospital Zurich, Zurich, Switzerland; 20 Second Department of Cardiol-
ogy, School of Medicine with the Division of Dentistry in Zabrze, Medical University of
Katowice, Katowice, Poland; 21 Department of Cardiology, University Hospital Brno,
Brno, Czech Republic and Medical Faculty, Masaryk University, Brno, Czech Republic.
Validation of a Novel High-Sensitivity Troponin I Assay
Clinical Chemistry 64:9 (2018) 1359
Internal Medicine, University Hospital Basel. The investigated hs-cTn
assays were donated by the manufacturers, who had no role in the
design of the study, the analysis of the data, the preparation of the
manuscript, or the decision to submit the manuscript for publication.
Expert Testimony: None declared.
Patents: None declared.
Role of Sponsor: The funding organizations played no role in the
design of study, choice of enrolled patients, review and interpretation of
data, or final approval of manuscript.
Acknowledgments: The authors thank the patients who participated
in the study and the emergency department staff as well as the
laboratory technicians of all participating sites for their most valu-
able efforts. In addition, the authors thank Irina Klimmeck, RN,
Fausta Chiaverio, RN (all University Hospital Basel, Switzerland),
Esther Garrido, MD, Isabel Campodarve, MD, Joachim Gea, MD
(Hospital del Mar, IMIM, Barcelona, Spain), Helena Man˜e´ Cruz,
Carolina Isabel Fuenzalida Inostroza (Hospital Clinic, Barcelona,
Spain), and Miguel Angel Garcı´a Brin˜o´n (Hospital Clı´nico San Carlos,
Madrid, Spain).
References
1. Pitts SR, Niska RW, Xu J, Burt CW. National Hospital
Ambulatory Medical Care Survey: 2006 emergency
department summary. Natl Health Stat Report 2008;
7:1–38.
2. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/
WHF Task Force for the Redeﬁnition of Myocardial In-
farction, Jaffe AS, Apple FS, et al. Universal deﬁnition of
myocardial infarction. Circulation 2007;116:2634–53.
3. Rofﬁ M, Patrono C, Collet J-P, Mueller C, Valgimigli M,
Andreotti F, et al. 2015 ESC guidelines for the manage-
ment of acute coronary syndromes in patients present-
ing without persistent ST-segment elevation. Eur Heart J
2016;37:267–315.
4. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B,
Blankenberg S, et al. How to use high-sensitivity cardiac
troponins in acute cardiac care. Eur Heart J 2012;33:
2252–7.
5. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS,
Katus HA. Analytical validation of a high-sensitivity car-
diac troponin T assay. Clin Chem 2010;56:254–61.
6. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C,
Hartwiger S, et al. Early diagnosis of myocardial infarc-
tionwith sensitive cardiac troponin assays.NEngl JMed
2009;361:858–67.
7. Rubini Gimenez M, Twerenbold R, Jaeger C, Schindler
C, Puelacher C,Wildi K, et al. One-hour rule-in and rule-
out of acutemyocardial infarction using high-sensitivity
cardiac troponin I. Am J Med 2015;128:861–70.
8. Shah ASV, Anand A, Sandoval Y, Lee KK, Smith SW, Ad-
amson PD, et al. High sensitivity cardiac troponin I at
presentation in patients with suspected acute coronary
syndrome: a cohort study. Lancet 2015;386:2481–8.
9. Rubini Gime´nez M, Hoeller R, Reichlin T, Zellweger C,
Twerenbold R, Reiter M, et al. Rapid rule out of acute
myocardial infarction using undetectable levels of high
sensitivity cardiac troponin. Int J Cardiol 2013;168:
3896–901.
10. Mueller C, Giannitsis E, Möckel M, Huber K, Mair J,
Plebani M, et al. Rapid rule out of acute myocardial
infarction: novel biomarker-based strategies. Eur
Heart J Acute Cardiovasc Care 2017;6:218–22.
11. Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH,
Parsonage WA, Hammett C, et al. Two-hour algorithm
for triage toward rule-out and rule-in of acute myocar-
dial infarction by use of high-sensitivity cardiac tro-
ponin I. Clin Chem 2016;62:494–504.
12. Nestelberger T, Wildi K, Boeddinghaus J, Twerenbold
R, Reichlin T, Gime´nezMR, et al. Characterization of the
observe zone of the ESC 2015 high-sensitivity cardiac
troponin 0h/1h-algorithm for the early diagnosis of
acute myocardial infarction. Int J Cardiol 2016;207:
238–45.
13. Boeddinghaus J, Twerenbold R, Nestelberger T, Wildi
K, Mueller C. Measurement of cardiac troponin for ex-
clusion of myocardial infarction. Lancet 2016;387:
2288.
14. Jaeger C,Wildi K, Twerenbold R, Reichlin T, Rubini Gime-
nezM,NeuhausJ-D,etal.One-hour rule-inandrule-outof
acute myocardial infarction using high-sensitivity cardiac
troponin I. AmHeart J 2016;171:92–102.
15. Reichlin T, Cullen L, Parsonage W, Greenslade J,
Twerenbold R, Moehring B, et al. Two-hour algorithm
for triage toward rule-out and rule-in of acute myocar-
dial infarction using high-sensitivity cardiac troponin T.
Am J Med 2015;128:369–79.
16. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM,
Greenslade J, et al. Two-hour accelerated diagnostic
protocol to assess patients with chest pain symptoms
using contemporary troponins as the only biomarker:
the ADAPT trial. J Am Coll Cardiol 2012;59:2091–8.
17. Meller B, Cullen L, Parsonage WA, Greenslade JH, Al-
dous S, Reichlin T, et al. Accelerated diagnostic protocol
using high-sensitivity cardiac troponin T in acute chest
pain patients. Int J Cardiol 2015;184:208–15.
18. ThanM, Aldous S, Lord SJ, Goodacre S, Frampton CMA,
Troughton R, et al. A 2-hour diagnostic protocol for pos-
sible cardiac chest pain in the emergency department:
a randomized clinical trial. JAMA Intern Med 2014;
174:51–8.
19. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter
M, Zellweger C, et al. One hour rule-out and rule-in of
acute myocardial infarction using high-sensitivity car-
diac troponin T. Arch Intern Med 2012;172:1211–8.
20. Neumann JT, Sörensen NA, Schwemer T, Ojeda F,
Bourry R, Sciacca V, et al. Diagnosis of myocardial in-
farction using a high-sensitivity troponin I 1-hour algo-
rithm. JAMA Cardiol 2016;1:397–404.
21. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer
W, Burkhalter H, et al. Utility of absolute and relative
changes in cardiac troponin concentrations in the early
diagnosis of acute myocardial infarction. Circulation
2011;124:136–45.
22. Wildi K, GimenezMR, Twerenbold R, Reichlin T, Jaeger
C, Heinzelmann A, et al. Misdiagnosis of myocardial
infarction related to limitations of the current regula-
tory approach to deﬁne clinical decision values for car-
diac troponin. Circulation 2015;131:2032–40.
23. BoeddinghausJ,ReichlinT,NestelbergerT, TwerenboldR,
Meili Y, Wildi K, et al. Early diagnosis of acute myocardial
infarction in patients with mild elevations of cardiac tro-
ponin. Clin Res Cardiol 2017;106:457–67.
24. Apple FS, Jaffe AS, Collinson P, Mockel M, Ordonez-
Llanos J, Lindahl B, et al. IFCC educational materials on
selected analytical and clinical applications of high sen-
sitivity cardiac troponin assays. Clin Biochem 2015;48:
201–3.
25. Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J, IFCC
Task Force on Clinical Applications of Cardiac Bio-
Markers. Cardiac troponin assays: guide to understand-
ing analytical characteristics and their impact on clinical
care. Clin Chem 2017;63:73–81.
26. Koerbin G, Tate J, Potter JM, Cavanaugh J, Glasgow N,
Hickman PE. Characterisation of a highly sensitive tro-
ponin I assay and its application to a cardio-healthy
population. Clin Chem Lab Med 2012;50:871–8.
27. Apple FS, Ler R, Murakami MM. Determination of 19
cardiac troponin I and T assay 99th percentile values
from a common presumably healthy population. Clin
Chem 2012;58:1574–81.
28. Krintus M, Kozinski M, Boudry P, Capell NE, Köller U,
Lackner K, et al. Europeanmulticenter analytical evalu-
ation of the Abbott ARCHITECT STAT high sensitive tro-
ponin I immunoassay. Clin Chem Lab Med 2014;52:
1657–65.
29. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL,
Hendriksen S, et al. Using standardized serum creati-
nine values in the modiﬁcation of diet in renal disease
study equation for estimating glomerular ﬁltration
rate. Ann Intern Med 2006;145:247–54.
30. Reichlin T, Twerenbold R, Wildi K, Gimenez MR,
Bergsma N, Haaf P, et al. Prospective validation of a
1-hour algorithm to rule-out and rule-in acute myocar-
dial infarction using a high-sensitivity cardiac troponin
T assay. CMAJ 2015;187:E243–52.
31. Mueller M, Biener M, Vafaie M, Doerr S, Keller T, Blan-
kenberg S, et al. Absolute and relative kinetic changes
of high-sensitivity cardiac troponin T in acute coronary
syndrome and in patients with increased troponin in
the absence of acute coronary syndrome. Clin Chem
2012;58:209–18.
32. Fonarow GC, Adams KF, AbrahamWT, Yancy CW, Boscar-
din WJ. Risk stratiﬁcation for in-hospital mortality in
acutelydecompensatedheart failure: classiﬁcationandre-
gression tree analysis. JAMA2005;293:572–80.
33. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classiﬁ-
cation and regression trees. Boca Raton (FL): Chapman
and Hall/CRC Press; 1984.
34. DeLong ER, DeLong DM, Clarke-Pearson DL. Compar-
ing the areas under two ormore correlated receiver op-
erating characteristic curves: a nonparametric ap-
proach. Biometrics 1988;44:837–45.
1360 Clinical Chemistry 64:9 (2018)
